- Home
- HALO
as 03-13-2025 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $61.63 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.43 | EPS Growth: | 63.33 |
| 52 Week Low/High: | $37.73 - $65.53 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,015,324,000 | Revenue Growth: | 22.44% |
| Revenue Growth (this year): | 20.06% | Revenue Growth (next year): | 23.87% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | HALO | Director | Mar 3 '25 | Sell | $58.53 | 5,000 | $293,458.31 | 33,611 | |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Feb 25 '25 | Sell | $58.40 | 21,697 | $1,260,680.74 | 175,453 | |
| Henderson Jeffrey William | HALO | Director | Feb 3 '25 | Sell | $56.17 | 5,000 | $281,516.80 | 33,611 | |
| Henderson Jeffrey William | HALO | Director | Jan 6 '25 | Sell | $50.01 | 10,000 | $500,060.00 | 33,611 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
HALO vs. AMGN: Which Stock Is the Better Value Option?
Insider Monkey
4 days ago
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
Barrons.com
7 days ago
AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.
Simply Wall St.
8 days ago
High Growth Tech Stocks To Watch In US March 2025
MT Newswires
8 days ago
Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version
The Wall Street Journal
9 days ago
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
Zacks
9 days ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
MT Newswires
9 days ago
Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.